Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data.
The RTS,S/AS candidate malaria vaccine has demonstrated efficacy against a variety of endpoints in Phase IIa and Phase IIb trials over more than a decade. A multi-country phase III trial of RTS,S/AS01 is now underway with submission as early as 2012, if vaccine safety and efficacy are confirmed. The immunologic basis for how the vaccine protects against both infection and disease remains uncertain. It is, therefore, timely to review the information currently available about the vaccine with regard to how it impacts the human-Plasmodium falciparum host-pathogen relationship. In this article, what is known about mechanisms involved in partial protection against malaria induced by RTS,S is reviewed.
Moorthy
Vasee S
VS
Initiative for Vaccine Research, World Health Organization, 1211 Geneva 27, Switzerland. moorthyv@who.int
Ballou
W Ripley
WR
D000818:Animals; D001549:Benzamides / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D006801:Humans; D017780:Malaria Vaccines / Q000276:immunology*; D016778:Malaria, Falciparum / Q000276:immunology* / Q000517:prevention & control*; D010963:Plasmodium falciparum / Q000276:immunology*; D011725:Pyridines / Q000494:pharmacology*
D001549:Benzamides; C576999:GRN-529; D017780:Malaria Vaccines; D011725:Pyridines; C526041:RTS,S-AS01B vaccine